Skip to content

Obstructive Sleep Apnea Treatment and Insulin Sensitivity in Pregnancy

Obstructive Sleep Apnea Treatment and Insulin Sensitivity in Pregnancy

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04013399
Enrollment
0
Registered
2019-07-09
Start date
2020-07-01
Completion date
2023-03-30
Last updated
2023-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insulin Sensitivity, Obstructive Sleep Apnea, Pregnancy Related

Brief summary

This study will evaluate the effect of treatment of obstructive sleep apnea on insulin sensitivity in pregnant women. Women in their third trimester of pregnancy will be randomized to receive treatment or no treatment for one month.

Detailed description

Obstructive Sleep Apnea (OSA) worsens over pregnancy and is related to increased risk of gestational diabetes. Despite the fact that sleep disturbances are common during pregnancy, OSA remains under-diagnosed, and poorly understood particularly in pregnancies affected by obesity. At least 25 percent of pregnancies are now affected by obesity, a leading risk factor for OSA, yet the effect of treatment of OSA on patterns of metabolic function and specifically decreased insulin sensitivity in pregnant women with obesity is a neglected area with major therapeutic implications to improve maternal health. Inflammation with OSA may decrease insulin sensitivity. Continuous positive airway pressure (CPAP) is a known effective treatment for OSA and has been shown to improve insulin sensitivity outside of pregnancy. Our overall hypothesis is that, compared with standard care, CPAP will improve nighttime breathing, blood and tissue oxygenation, decrease markers of inflammation, and increase insulin sensitivity. Using a randomized controlled trial, we will determine the effect of CPAP on metabolic dysfunction induced by OSA in pregnant women with obesity.

Interventions

DEVICEContinuous Positive Airway Pressure

The device is an auto-adjusting pressure device with an integrated humidifier. Pressure is adjusted based on airway resistance.

Sponsors

Washington University School of Medicine
CollaboratorOTHER
Barnes-Jewish Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 39 Years
Healthy volunteers
Yes

Inclusion criteria

* 28-32 weeks pregnant * Age 20-39 * BMI 30-40 kg/m2 pre-pregnancy (or first trimester) * Obstructive Sleep Apnea (AHI≥15) * Have a singleton pregnancy

Exclusion criteria

* Diabetes (GDM, type 1 or type 2) * Using beta blockers or glucocorticoids * Have children who are ≤2 yrs old (risk of disrupted sleep) * Diagnosed sleep disorders (other than sleep apnea) * Night work schedule * Diagnosed congestive heart failure * Diagnosed lung disease (e.g. asthma, chronic obstructive pulmonary disease) * Pre-gestational hypertension

Design outcomes

Primary

MeasureTime frameDescription
Degree of Insulin Sensitivity measured by Matsuda Index by Oral glucose Tolerance Test1 monthChange in whole body insulin sensitivity measured using Matsuda Index
Percent of Oxygen in blood by pulse oximetry1 monthChange in oxygen saturation measured by pulse oximetry

Secondary

MeasureTime frameDescription
Percent of Oxygen in Adipose Tissue measured by oxygen tension probe1 monthChange in adipose tissue oxygenation measured by oxygen tension
Concentration of inflammatory gene expression in adipose Tissue measured by RNA and DNA sequencing1 monthChange in adipose tissue gene expression of inflammatory markers

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026